(Q37831353)

24 August 2017

1 reference

title

Ivabradine: recent and potential applications in clinical practice (English)

1 reference

24 August 2017

Graziano Riccioni

1

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 February 2011

1 reference

Expert Opinion on Pharmacotherapy

24 August 2017

published in

1 reference

24 August 2017

volume

12

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

443-450

1 reference

Heart rate and cardiovascular mortality: the Framingham Study

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Heart rate as a risk factor for cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Influence of heart rate on mortality after acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Heart rate as a treatable cardiovascular risk factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Heart rate, autonomic markers, and cardiac mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Heart rate, ischaemic heart disease, and sudden cardiac death in middle-aged British men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Resting heart rate in cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Metabolic effects of pindolol and propranolol in a double-blind cross-over study in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Emerging medical treatment for angina pectoris.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Heart rate in ischemic heart disease. The innovation of ivabradine: more than pure heart rate reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Ivabradine: from molecular basis to clinical effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

The cardiac pacemaker current

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

The funny current: cellular basis for the control of heart rate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

The role of the funny current in pacemaker activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Efficacy of ivabradine, a selective I(f) inhibitor, in patients with chronic stable angina pectoris and diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Focus on ivabradine: a new heart rate-controlling drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Novel If current inhibitor ivabradine: safety considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Angina: Ivabradine for treatment of stable angina pectoris

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Treatment of stable angina pectoris by ivabradine in every day practice: the REDUCTION study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Efficacy of I(f) inhibition with ivabradine in different subpopulations with stable angina pectoris

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Sinus tachyarrhythmias and the specific bradycardic agents: a marriage made in heaven?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Efficacy of ivabradine administration in patients affected by inappropriate sinus tachycardia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

A case of inappropriate sinus tachycardia after atrio-ventricular nodal reentrant tachycardia cryoablation successfully treated by ivabradine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Ivabradine as an alternative therapeutic trial in the therapy of inappropriate sinus tachycardia: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Ivabradine to treat inappropriate sinus tachycardia after the fast pathway ablation in a patient with severe pectus excavatum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

A case of cardiomyopathy induced by inappropriate sinus tachycardia and cured by ivabradine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Ivabradine: appropriate treatment for inappropriate sinus tachycardia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Symptom improvement in postural orthostatic tachycardia syndrome with the sinus node blocker ivabradine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Heart rate reduction after heart transplantation with beta-blocker versus the selective If channel antagonist ivabradine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Effects of ivabradine on allograft function and exercise performance in heart transplant recipients with permanent sinus tachycardia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Heart rate reduction for 12 months with ivabradine reduces left ventricular mass in cardiac allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Cardiogenic shock due to tachycardiomyopathy after heart transplantation: successful treatment with ivabradine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Comparison of ivabradine versus metoprolol in early phases of reperfused anterior myocardial infarction with impaired left ventricular function: preliminary findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Antiatherosclerotic effects of beta-blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Defying the economists: a decrease in heart rate improves not only cardiac but also endothelial function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Heart rate reduction with ivabradine improves erectile dysfunction in parallel to decrease in atherosclerotic plaque load in ApoE-knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Randomised, double-blind, placebo-controlled trial of ivabradine in patients with acute coronary syndrome: effects of the If current inhibitor ivabradine on reduction of inflammation markers in patients with acute coronary syndrome--RIVIERA trial st

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Projections of global mortality and burden of disease from 2002 to 2030

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

Economic burden of cardiovascular diseases in the enlarged European Union

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.548321

10.1517/14656566.2011.548321

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference